Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Daniele Parenti

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Biotechnology Advances|August 23, 2011
Advances and applications of binding affinity prediction methods in drug discoveryMarco Daniele Parenti, Giulio Rastelli
Bioorganic & Medicinal Chemistry Letters|September 3, 2003
Structure of Plasmodium vivax dihydrofolate reductase determined by homology modeling and molecular dynamics refinementGiulio Rastelli, Sara Pacchioni, Marco Daniele Parenti
Journal of Biomolecular Screening|November 19, 2010
BEAR, a novel virtual screening methodology for drug discoveryGianluca Degliesposti, Corinne Portioli, Marco Daniele Parenti, et al.
Molecular Biosystems|June 11, 2015
Selectivity hot-spots of sirtuin catalytic coresMarco Daniele Parenti, Santina Bruzzone, Alessio Nencioni, et al.
Journal of Medicinal Chemistry|August 6, 2004
Three-dimensional quantitative structure-activity relationship analysis of a set of Plasmodium falciparum dihydrofolate reductase inhibitors using a pharmacophore generation approachMarco Daniele Parenti, Sara Pacchioni, Anna Maria Ferrari, et al.
Current Pharmaceutical Design|September 29, 2012
Modulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectivesFederico Andreoli, Arménio Jorge Moura Barbosa, Marco Daniele Parenti, et al.
Journal of Medicinal Chemistry|June 27, 2003
Docking and database screening reveal new classes of Plasmodium falciparum dihydrofolate reductase inhibitorsGiulio Rastelli, Sara Pacchioni, Worachart Sirawaraporn, et al.
Current Pharmaceutical Design|September 29, 2012
Rejuvenating sirtuins: the rise of a new family of cancer drug targetsSantina Bruzzone, Marco Daniele Parenti, Alessia Grozio, et al.
Cancers|February 26, 2025
The Evolution of Anticancer 3D In Vitro Models: The Potential Role of Machine Learning and AI in the Next Generation of Animal-Free ExperimentsCarolina Momoli, Beatrice Costa, Lorenzo Lenti, et al.
Cancers|April 14, 2025
Correction: Momoli et al. The Evolution of Anticancer 3D In Vitro Models: The Potential Role of Machine Learning and AI in the Next Generation of Animal-Free Experiments. <i>Cancers</i> 2025, <i>17</i>, 700Carolina Momoli, Beatrice Costa, Lorenzo Lenti, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Biotechnology Advances|August 23, 2011
Advances and applications of binding affinity prediction methods in drug discoveryMarco Daniele Parenti, Giulio Rastelli
Bioorganic & Medicinal Chemistry Letters|September 3, 2003
Structure of Plasmodium vivax dihydrofolate reductase determined by homology modeling and molecular dynamics refinementGiulio Rastelli, Sara Pacchioni, Marco Daniele Parenti
Journal of Biomolecular Screening|November 19, 2010
BEAR, a novel virtual screening methodology for drug discoveryGianluca Degliesposti, Corinne Portioli, Marco Daniele Parenti, et al.
Molecular Biosystems|June 11, 2015
Selectivity hot-spots of sirtuin catalytic coresMarco Daniele Parenti, Santina Bruzzone, Alessio Nencioni, et al.
Journal of Medicinal Chemistry|August 6, 2004
Three-dimensional quantitative structure-activity relationship analysis of a set of Plasmodium falciparum dihydrofolate reductase inhibitors using a pharmacophore generation approachMarco Daniele Parenti, Sara Pacchioni, Anna Maria Ferrari, et al.
Current Pharmaceutical Design|September 29, 2012
Modulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectivesFederico Andreoli, Arménio Jorge Moura Barbosa, Marco Daniele Parenti, et al.
Journal of Medicinal Chemistry|June 27, 2003
Docking and database screening reveal new classes of Plasmodium falciparum dihydrofolate reductase inhibitorsGiulio Rastelli, Sara Pacchioni, Worachart Sirawaraporn, et al.
Current Pharmaceutical Design|September 29, 2012
Rejuvenating sirtuins: the rise of a new family of cancer drug targetsSantina Bruzzone, Marco Daniele Parenti, Alessia Grozio, et al.
Cancers|February 26, 2025
The Evolution of Anticancer 3D In Vitro Models: The Potential Role of Machine Learning and AI in the Next Generation of Animal-Free ExperimentsCarolina Momoli, Beatrice Costa, Lorenzo Lenti, et al.
Cancers|April 14, 2025
Correction: Momoli et al. The Evolution of Anticancer 3D In Vitro Models: The Potential Role of Machine Learning and AI in the Next Generation of Animal-Free Experiments. <i>Cancers</i> 2025, <i>17</i>, 700Carolina Momoli, Beatrice Costa, Lorenzo Lenti, et al.
Pageof 3